Amphastar Pharmaceuticals Inc. (NASDAQ:AMPH) traded down 3.5% during trading on Wednesday . The company traded as low as $20.17 and last traded at $20.52, with a volume of 809,894 shares changing hands. The stock had previously closed at $21.26.

A number of equities research analysts recently commented on the stock. Piper Jaffray Cos. restated an “overweight” rating and issued a $22.00 price objective on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 11th. Jefferies Group raised their price objective on shares of Amphastar Pharmaceuticals from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Tuesday, August 9th. BMO Capital Markets restated a “hold” rating and issued a $17.00 price objective on shares of Amphastar Pharmaceuticals in a research report on Tuesday, August 9th. Zacks Investment Research upgraded shares of Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating and set a $18.00 price objective for the company in a research report on Monday, August 1st. Finally, Needham & Company LLC raised their price objective on shares of Amphastar Pharmaceuticals from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Tuesday, August 9th. Two research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company’s stock. Amphastar Pharmaceuticals presently has a consensus rating of “Buy” and an average target price of $20.00.

The company has a market capitalization of $943.03 million, a P/E ratio of 67.86 and a beta of 1.83. The stock’s 50 day moving average price is $18.56 and its 200-day moving average price is $15.35.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/amphastar-pharmaceuticals-inc-amph-stock-price-down-3-5.html

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its earnings results on Monday, August 8th. The company reported $0.23 EPS for the quarter, topping the consensus estimate of $0.01 by $0.22. Amphastar Pharmaceuticals had a net margin of 5.19% and a return on equity of 4.71%. The firm earned $68 million during the quarter, compared to analysts’ expectations of $62.10 million. During the same quarter in the prior year, the firm earned ($0.09) EPS. Amphastar Pharmaceuticals’s quarterly revenue was up 26.4% on a year-over-year basis. Analysts anticipate that Amphastar Pharmaceuticals Inc. will post $0.37 earnings per share for the current year.

In other Amphastar Pharmaceuticals news, General Counsel Jason B. Shandell sold 10,000 shares of the company’s stock in a transaction dated Monday, August 22nd. The shares were sold at an average price of $19.95, for a total value of $199,500.00. Following the completion of the transaction, the general counsel now owns 212,961 shares in the company, valued at approximately $4,248,571.95. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO William J. Peters sold 2,297 shares of the company’s stock in a transaction dated Monday, July 18th. The stock was sold at an average price of $17.76, for a total transaction of $40,794.72. Following the completion of the transaction, the chief financial officer now owns 64,652 shares of the company’s stock, valued at approximately $1,148,219.52. The disclosure for this sale can be found here. 29.30% of the stock is currently owned by company insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of AMPH. State Street Corp boosted its position in Amphastar Pharmaceuticals by 3.8% in the first quarter. State Street Corp now owns 662,582 shares of the company’s stock valued at $7,949,000 after buying an additional 24,205 shares during the period. Los Angeles Capital Management & Equity Research Inc. purchased a new position in Amphastar Pharmaceuticals during the first quarter valued at approximately $180,000. UBS Asset Management Americas Inc. boosted its position in Amphastar Pharmaceuticals by 10.0% in the first quarter. UBS Asset Management Americas Inc. now owns 277,294 shares of the company’s stock valued at $3,328,000 after buying an additional 25,095 shares during the period. Acadian Asset Management LLC boosted its position in Amphastar Pharmaceuticals by 43.4% in the first quarter. Acadian Asset Management LLC now owns 452,371 shares of the company’s stock valued at $5,428,000 after buying an additional 136,816 shares during the period. Finally, Menta Capital LLC purchased a new position in Amphastar Pharmaceuticals during the first quarter valued at approximately $533,000. Hedge funds and other institutional investors own 35.87% of the company’s stock.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses primarily on developing, manufacturing, marketing and selling generic and injectable and inhalation products. The Company has two segments: finished pharmaceutical products and active pharmaceutical ingredients (API) products.

5 Day Chart for NASDAQ:AMPH

Receive News & Ratings for Amphastar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.